The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
- 1 January 2011
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 650 (2-3), 703-707
- https://doi.org/10.1016/j.ejphar.2010.10.062
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Vildagliptin in clinical practice: a review of literatureExpert Opinion on Pharmacotherapy, 2009
- Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in miceEuropean Journal of Pharmacology, 2005
- Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant RatsJournal of Pharmacology and Experimental Therapeutics, 2005
- Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in MiceEndocrinology, 2005
- Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous SystemEndocrinology, 2004
- Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistanceProceedings of the National Academy of Sciences of the United States of America, 2003
- GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes/Metabolism Research and Reviews, 2003
- β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 DiabetesDiabetes, 2003
- beta-cell turnover: its assessment and implications.Diabetes, 2001